Entinostat

Generic Name: Entinostat

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₀N_₄O_₃

CAS Number: 209783-80-2

Unique Ingredient Identifier: 1ZNY4FKK9H

Background: Entinostat is under investigation for the treatment and other of Volunteers, Breast Cancer, Human Volunteers, and Normal Volunteers. Entinostat has been investigated for the treatment of Non-Small Lung Cancer, Epigenetic Therapy.

Indication: 联合芳香化酶抑制剂用于治疗激素受体（HR）阳性、人类表皮生长因子受体-2（HER-2）阴性，经内分泌治疗复发或进展的局部晚期或转移性乳腺癌患者。

Clinical Trials

Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer

Phase 2

Completed

Conditions: ER+ Breast Cancer
Breast Cancer
Estrogen Receptor-Positive Breast Cancer
Breast Cancer, Estrogen Receptor-Positive

Interventions: Drug: entinostat
Drug: Placebo
Drug: exemestane

First Posted Date: 2008-05-13

Last Posted Date: 2022-05-11

Lead Sponsor: Syndax Pharmaceuticals

Target Recruit Count: 130

Registration Number: NCT00676663

Locations: 🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Memorial Cancer Institute, Hollywood, Florida, United States

and more 35 locations

Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

Phase 1

Completed

Conditions: Carcinoma, Non-Small Cell Lung
Non-Small-Cell Lung Carcinoma

Interventions: Drug: Entinostat
Drug: Placebo
Drug: Erlotinib

First Posted Date: 2008-01-28

Last Posted Date: 2022-08-22

Lead Sponsor: Syndax Pharmaceuticals

Target Recruit Count: 141

Registration Number: NCT00602030

Locations: 🇺🇸
Fairfax Northern Virginia Hematology-Oncology, Fairfax, Virginia, United States
🇺🇸
HOPE (Hematology Oncology Physicians & Extenders), Tucson, Arizona, United States
🇺🇸
Oncology Associates of Oregon, Eugene, Oregon, United States

and more 18 locations

MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Adult Acute Myeloblastic Leukemia With Maturation (M2)
Untreated Adult Acute Myeloid Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Erythroleukemia (M6a)
de Novo Myelodysplastic Syndromes

Interventions: Drug: entinostat
Drug: sargramostim

First Posted Date: 2007-04-19

Last Posted Date: 2017-07-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00462605

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Recurrent Non-Small Cell Lung Carcinoma
Stage IIIA Non-Small Cell Lung Cancer
Stage IIIB Non-Small Cell Lung Cancer
Stage IV Non-Small Cell Lung Cancer

Interventions: Drug: Azacitidine 30mg/m2
Drug: Azacitidine 40mg/m2
Drug: Entinostat

First Posted Date: 2006-10-13

Last Posted Date: 2019-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 94

Registration Number: NCT00387465

Locations: 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Sidney Kimmel Cancer Center, San Diego, California, United States

and more 2 locations

Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1
Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL
Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA
Alkylating Agent-Related Acute Myeloid Leukemia
Recurrent Adult Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia

Interventions: Drug: Azacitidine
Other: Laboratory Biomarker Analysis
Drug: Entinostat

First Posted Date: 2006-04-12

Last Posted Date: 2017-02-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 197

Registration Number: NCT00313586

Locations: 🇺🇸
Clements University Hospital, Dallas, Texas, United States
🇺🇸
Union Hospital of Cecil County, Elkton, Maryland, United States
🇺🇸
Hematology and Oncology Associates, Chicago, Illinois, United States

and more 231 locations

MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
de Novo Myelodysplastic Syndrome
Leukemia
Myelodysplastic Syndrome
Recurrent Adult Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Secondary Myelodysplastic Syndrome

Interventions: Drug: Azacitidine
Drug: Entinostat

First Posted Date: 2005-01-10

Last Posted Date: 2019-10-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 63

Registration Number: NCT00101179

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Mount Sinai Hospital, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas

Phase 1

Completed

Conditions: Adult Grade III Lymphomatoid Granulomatosis
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Intraocular Lymphoma
Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Adult T-cell Leukemia/Lymphoma

Interventions: Drug: entinostat
Drug: isotretinoin

First Posted Date: 2004-12-09

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00098891

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

MS-275 in Treating Patients With Hematologic Cancer

Phase 1

Completed

Conditions: Leukemia
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2003-01-27

Last Posted Date: 2010-03-10

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Registration Number: NCT00015925

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2012-03-15

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 75

Registration Number: NCT00020579

Locations: 🇺🇸
National Naval Medical Center, Bethesda, Maryland, United States
🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy